New York State Common Retirement Fund Sells 31,493 Shares of Nurix Therapeutics, Inc. $NRIX

New York State Common Retirement Fund cut its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 59.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,195 shares of the company’s stock after selling 31,493 shares during the quarter. New York State Common Retirement Fund’s holdings in Nurix Therapeutics were worth $196,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its holdings in shares of Nurix Therapeutics by 118.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after buying an additional 3,475 shares during the last quarter. Velan Capital Investment Management LP purchased a new position in Nurix Therapeutics in the 2nd quarter worth approximately $114,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Nurix Therapeutics in the 2nd quarter valued at approximately $141,000. Sei Investments Co. bought a new position in Nurix Therapeutics in the 2nd quarter valued at approximately $158,000. Finally, KLP Kapitalforvaltning AS boosted its stake in Nurix Therapeutics by 38.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 15,400 shares of the company’s stock valued at $175,000 after purchasing an additional 4,300 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on NRIX shares. Piper Sandler upped their price target on Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Thursday, January 29th. Mizuho upped their target price on shares of Nurix Therapeutics from $24.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of Nurix Therapeutics in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company dropped their target price on shares of Nurix Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Nurix Therapeutics Trading Down 2.1%

NASDAQ NRIX opened at $16.11 on Thursday. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $22.50. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -5.30 and a beta of 1.96. The company’s 50 day moving average is $18.42 and its two-hundred day moving average is $13.65.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Wednesday, January 28th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. The firm had revenue of $13.58 million during the quarter, compared to analysts’ expectations of $13.41 million. Sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 3,661 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $60,772.60. Following the sale, the chief financial officer owned 45,427 shares in the company, valued at $754,088.20. This trade represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gwenn Hansen sold 4,895 shares of the business’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00. Following the completion of the sale, the insider owned 83,672 shares in the company, valued at approximately $1,388,955.20. This trade represents a 5.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 7.40% of the company’s stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.